News on the latest discoveries and experiments for the treatment and diagnosis of Cardiomyopathies.
The utmost attention should be paid to checking the operation of the Emblem A209-A219 subcutaneous defibrillators as the device may need to be replaced due to premature and accelerated battery depletion.
In the last year it has happened that patients suffering from obstructive hypertrophic cardiomyopathy did not find an essential drug available for their therapy.
The antiarrhythmic drug Ritmodan and Ritmodan Retard are still unavailable in Italian pharmacies. Aifa has again postponed the deadline for the shortage and, as regards the Ritmodan Retard, it seems that we will have to wait until at least mid-February 2022.
What does “shared decision-making” mean. Lisa Salberg founder and CEO of the American Association for Hypertrophic Myocarditis (HCMA) sent a video message to the "Advances in Cardiomyopathies" conference on 9-10 September, explaining how the concept is implemented in the United States. “We want patients to be excited about the future and understand their options and know how to ask smart questions that will help them achieve their goals,” he said. We publish broad passages from the speech that provide important elements for the discussion on the subject in Italy
We are told by prof. Bruno Cacopardo the work of an excellent group of Singapore researchers comparing the clinical and virological effects of the infection between vaccinated and unvaccinated. In this study it appears that, in addition to the well-known clinical protection (none of the vaccinated die and nobody goes to hospital), in the vaccinated the time of decline of the viral load (even if starting from the same concentration [...]
In the last ten years, numerous research projects have been funded to identify new molecules capable of interacting directly on cardiac cells (“Cardiomyocytes”).
